Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Pharma Mar's Capital Expenditure for the
three
months ended in Mar. 2026 was €-1.35 Mil. Its Revenue for the
three
months ended in Mar. 2026 was €42.90 Mil.
Hence, Pharma Mar's Capex-to-Revenue for the
three
months ended in Mar. 2026 was 0.03.
Pharma Mar (FRA:PMRA) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Pharma Mar Capex-to-Revenue Related Terms
Pharma Mar Capex-to-Revenue Historical Data
* Premium members only.
The historical data trend for Pharma Mar's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PMRA vs VRTX, REGN, ALNY: Capex-to-Revenue Comparison
For the Biotechnology subindustry, Pharma Mar's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar Capex-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pharma Mar's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (FRA:PMRA) has a Capex-to-Revenue of 0.03 as of Mar. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Capex-to-Revenue too high?
Pharma Mar's current Capex-to-Revenue is 0.03. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Capex-to-Revenue compare to VRTX and REGN?
Pharma Mar's Capex-to-Revenue of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Biotechnology company?
A good Capex-to-Revenue depends on the Biotechnology industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Pharma Mar and its competitors. Pharma Mar's current Capex-to-Revenue is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.05 — trading 18.4% below its estimated fair value. The current Capex-to-Revenue is 0.03. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current Capex-to-Revenue is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (FRA:PMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €68.05 is trading 18.4% below its estimated GF Value™ of €83.37.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for FRA:PMRA:
Capex-to-Revenue: 0.03
GF Value™: €83.37 vs. price of €68.05 (18.4% below fair value)
No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score
Get the complete analysis for FRA:PMRA
Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PMRA has been successfully added to your 
